Five Prime Therapeutics Inc

Five Prime Therapeutics — Technical Presentation (November 2020)

14 slides from Five Prime Therapeutics's technical presentation, Nov 10, 2020

  1. Slide 1: Bemarituzumab Targeted Therapy for FGFR2b+ Tumors

    Exhibit 99.2 Bemarituzumab Targeted Therapy for FGFR2b+ Tumors November 10, 2020 © 2020 Five Prime Therapeutics, Inc.Exhibit 99.2 Bemarituzumab Targeted Therapy for FGFR2b+ Tumors November 10, 2020 © 2020 Five Prime Therapeutics, Inc.

  2. Slide 2: Forward-Looking Statements Disclaimer

    Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate and similar expressions (as well as other words or expressions referencing future

  3. Slide 3: Executive Summary: Bemarituzumab Value Proposition

    Executive Summary: Bemarituzumab Value Proposition targeting FGFR2b+ advanced gastric and First-in-class gastroesophageal junction (GC/GEJ) cancers antibody FIGHT Phase 2 Results PFS, OS, ORR PFS HR=0.68 (95% CI: 0.44-1.04; p=0.073) statistically OS HR=0.58 (95% CI: 0.35-0.95; p=0.027) 1 significant

  4. Slide 4: Gastric Cancer Has Global Impact and a Poor Prognosis

    Gastric Cancer Has Global Impact and a Poor Prognosis 1 Gastric Cancer Incidence 1 million+ cases globally 1M+ each year rd 3 most common cause 1 of cancer death globally 3rd After lung and breast cancer 5th Most 1 Common Cancer After lung, breast, prostate 5th and colon cancer Unmet Medical Need 2

  5. Slide 5: Bemarituzumab (Bema) MoA

    Bemarituzumab (Bema) MoA © © 2 202 020 0 F Fiiv ve e P Pr riim me e T The her ra ape peu ut tiic cs s, , I In nc c. . 5Bemarituzumab (Bema) MoA © © 2 202 020 0 F Fiiv ve e P Pr riim me e T The her ra ape peu ut tiic cs s, , I In nc c. . 5

  6. Slide 6: Overview of Bemarituzumab Clinical Development

    Overview of Bemarituzumab Clinical Development Study Objective(s) Results FGFR2b Selected Number of patients Phase 1 Monotherapy Tolerability, safety and preliminary efficacy of monotherapy ORR 18% in late-line FGFR2b+ Gastric / Mixed 1 (n=79) in late-line patients GEJ Phase 1 Monotherapy Tolerabili

  7. Slide 7: FIGHT: Phase 2 Randomized Trial in Frontline FGFR2b+, non HER2+ Gastric/GEJ Cancers

    FIGHT: Phase 2 Randomized Trial in Frontline FGFR2b+, non HER2+ Gastric/GEJ Cancers fiveprime.com | NASDAQ: FPRX © © 2 202 020 0 F Fiiv ve e P Pr riim me e T The her ra ape peu ut tiic cs s, , I In nc c. . 7FIGHT: Phase 2 Randomized Trial in Frontline FGFR2b+, non HER2+ Gastric/GEJ Cancers fiveprime

  8. Slide 8: FIGHT Trial Design

    FIGHT Trial Design Patients Selected for FGFR2b+ Tumors (~30% of all non-HER2+ Gastric/GEJ Cancer) Key Eligibility Criteria • No prior therapy for unresectable Bema + mFOLFOX6 locally advanced or metastatic Primary endpoint (n = 77) gastric or GEJ adenocarcinoma Progression-Free • RECIST v1.1 evalua

  9. Slide 9: Primary and Secondary Efficacy Endpoints with Statistical Significance

    Favor Placebo 1 Primary and Secondary Efficacy Endpoints with Statistical Significance Hazard Ratio MEDIAN PFS/OS (MON) HR (95% CI) ENDPOINT RESPONSE RATE DIFFERENCE IN ORR (95% CI) 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 Bema: 9.5 0.68 (0.44, 1.04) PFS Placebo: 7.4 p=0.073 Bema: NR 0.58 (0.35, 0.95) OS P

  10. Slide 10: Results from Front-Line Gastric Cancer Trials

    Results from Front-Line Gastric Cancer Trials ToGA Trial CheckMate-649 Trial FIGHT Trial (nivolumab; CPS ≥5/HER2-) (bema; FGFR2b+/non HER2+) (trastuzumab; HER2+) Global including Global not including Global including Endpoint South Korea & Japan South Korea or Japan South Korea & Japan HR = 0.71 HR

  11. Slide 11: Summary of Treatment-Emergent Adverse Events (TEAEs)

    Summary of Treatment-Emergent Adverse Events (TEAEs) Bema (N = 76) Placebo (N = 77) Total (N = 153) All TEAE 76 (100.0%) 76 (98.7%) 152 (99.3%) Grade ≥ 3 63 (82.9%) 57 (74.0%) 120 (78.4%) Leading to death (Grade 5) 5 (6.6%) 4 (5.2%) 9 (5.9%) SAE 24 (31.6%) 28 (36.4%) 52 (34.0%) SAE related to any st

  12. Slide 12: Summary of FIGHT Phase 2 Top-Line Results

    Summary of FIGHT Phase 2 Top-Line Results Primary endpoint Secondary efficacy endpoints st 1 secondary endpoint OS: Bema is superior to Primary endpoint PFS: Bema is superior to placebo placebo 1 • HR = 0.68 (95% CI: 0.44, 1.04; p=0.073 ) 1 • HR = 0.58 (95% CI: 0.35, 0.95; p=0.027 ) • Median PFS (mo

  13. Slide 13: Potential Development Opportunity in Other FGFR2b+ Tumors

    Potential Development Opportunity in Other FGFR2b+ Tumors FGFR2b+ Rate Estimated Global 1 Tumor Type Global Prevalence (2+ / 3+ IHC Cutoff) FGFR2b+ Population (Study source) 31% NSCLC-Squamous 543,141 ~150,000 (Ventana data, n=100) 13% TNBC 825,012 ~100,000 (Five Prime data, n=97) 40% Ovarian cancer

  14. Slide 14: Bemarituzumab Targeted Therapy for FGFR2b+ Tumors

    Bemarituzumab Targeted Therapy for FGFR2b+ Tumors November 10, 2020 © 2020 Five Prime Therapeutics, Inc.Bemarituzumab Targeted Therapy for FGFR2b+ Tumors November 10, 2020 © 2020 Five Prime Therapeutics, Inc.

Five Prime Therapeutics — Technical Presentation (November 2020) on 6ix